SynCore Biotechnology Co Ltd Cash Flow Conversion Efficiency
SynCore Biotechnology Co Ltd cash flow conversion efficiency. Based on the latest financial reports, SynCore Biotechnology Co Ltd (4192) has a cash flow conversion efficiency ratio of -0.028x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-7.18 Million ≈ $-226.11K USD) by net assets (NT$257.97 Million ≈ $8.13 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of SynCore Biotechnology Co Ltd (2015–2024)
Cash flow conversion efficiency of SynCore Biotechnology Co Ltd from 2015 to 2024. This chart illustrates how SynCore Biotechnology Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of SynCore Biotechnology Co Ltd for real-time trading data and today's change.
SynCore Biotechnology Co Ltd Cash Flow Conversion Ratio Explained
SynCore Biotechnology Co Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
SynCore Biotechnology Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of SynCore Biotechnology Co Ltd ranked by their cash flow conversion efficiency. Also see SynCore Biotechnology Co Ltd stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Global Menkul Degerler AS
IS:GLBMD
|
0.070x |
|
Rocketdna Ltd
AU:RKT
|
-0.088x |
|
Fitzroy River Corporation Ltd
AU:FZR
|
0.062x |
|
Hanchang Ind.Co.Ltd
KQ:079170
|
0.048x |
|
Dragonfly Energy Holdings Corp.
NASDAQ:DFLI
|
-0.080x |
|
SSP Group PLC
LSE:SSPG
|
1.962x |
|
Caspin Resources Ltd
AU:CPN
|
-0.288x |
|
Neurotech International Ltd
AU:NTI
|
-0.063x |
Annual Cash Flow Conversion Efficiency for SynCore Biotechnology Co Ltd (2015–2024)
The table below shows the annual cash flow conversion efficiency of SynCore Biotechnology Co Ltd from 2015 to 2024. Review 4192 financial flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$294.69 Million ≈ $9.28 Million |
NT$-49.24 Million ≈ $-1.55 Million |
-0.167x | +27.55% |
| 2023-12-31 | NT$357.14 Million ≈ $11.25 Million |
NT$-82.37 Million ≈ $-2.60 Million |
-0.231x | +72.60% |
| 2022-12-31 | NT$249.01 Million ≈ $7.85 Million |
NT$-209.61 Million ≈ $-6.60 Million |
-0.842x | -62.20% |
| 2021-12-31 | NT$442.92 Million ≈ $13.95 Million |
NT$-229.86 Million ≈ $-7.24 Million |
-0.519x | +8.12% |
| 2020-12-31 | NT$560.58 Million ≈ $17.66 Million |
NT$-316.63 Million ≈ $-9.98 Million |
-0.565x | +17.41% |
| 2019-12-31 | NT$612.03 Million ≈ $19.28 Million |
NT$-418.57 Million ≈ $-13.19 Million |
-0.684x | -77.52% |
| 2018-12-31 | NT$706.70 Million ≈ $22.26 Million |
NT$-272.26 Million ≈ $-8.58 Million |
-0.385x | -37.46% |
| 2017-12-31 | NT$720.61 Million ≈ $22.70 Million |
NT$-201.96 Million ≈ $-6.36 Million |
-0.280x | -38.83% |
| 2016-12-31 | NT$966.36 Million ≈ $30.45 Million |
NT$-195.09 Million ≈ $-6.15 Million |
-0.202x | -9.04% |
| 2015-12-31 | NT$842.81 Million ≈ $26.55 Million |
NT$-156.03 Million ≈ $-4.92 Million |
-0.185x | -- |
About SynCore Biotechnology Co Ltd
SynCore Biotechnology Co.,Ltd, engages in development and sale of food advisory, medicine inspection, and biotechnology service in Taiwan. The company is involved in the development of SB01, an injectable anti-cancer new ingredient (NCE) that is in Phase II clinical trials for the treatment of head and neck cancer; and SB02, an anti-cancer NCE, which is in preclinical research for use in the trea… Read more